Studie MK-3475 - 590

MK-3475 - 590

ENDE DER REKRUTIERUNG!!!

A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab (MK-3475) in Combination with Cisplatin and 5-Fluorouracil versus Placebo in Combination with Cisplatin and 5-Fluorouracil as First-Line Treatment in Subjects with Advanced/Metastatic Esophageal Carcinoma (KEYNOTE-590)

NCT03189719

3. Med 3. Med Ismaninger Str. 22 81675 München Germany

III

Rekrutierung beendet

Unbekannt / Unbekannt

Chemo,Zielgerichtet